불임 치료 서비스 시장 규모, 점유율, 동향 및 예측 : 불임 원인, 시술, 서비스, 최종사용자, 지역별(2026-2034년)

The global fertility services market size was valued at USD 51.9 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 150.2 Billion by 2034, exhibiting a CAGR of 12.15% from 2026-2034. Asia Pacific currently dominates the market, holding a market share of 30% in 2025. The region benefits from its expanding population base, increasing rates of infertility attributed to lifestyle-related factors and delayed family planning, rising income levels facilitating access to reproductive healthcare, and a growing network of specialized fertility clinics, all contributing to the Asia Pacific fertility services market share.

The fertility services market growth is driven by the rising cases of infertility in both developed and developing nations, thus encouraging more individuals and couples to turn to fertility services. The rising number of late pregnancies, lifestyle-related health problems, and the growing number of cases of reproductive disorders are steadily increasing the global patient base. The growing acceptance of fertility services such as egg freezing and surrogacy, as well as government insurance mandates, are making fertility services more accessible. The growing number of fertility clinics, advancements in cryopreservation and genetic screening, and growing awareness about healthcare are all factors that are driving the fertility services market.

The United States has emerged as a major region in the fertility services market owing to many factors. The country hosts one of the most advanced and well-established reproductive healthcare ecosystems globally, supported by world-class medical infrastructure, highly trained reproductive endocrinologists, and a robust network of accredited fertility centers. In October 2025, the U.S. government announced a policy initiative to lower the cost of in-vitro fertilization (IVF) medications and expand access to fertility coverage, including standalone IVF benefits and discounted drugs. Significant demand is driven by the growing trend of delayed parenthood among working professionals, increasing same-sex couple family formation, and rising infertility rates linked to lifestyle and environmental factors. Additionally, employer-sponsored fertility benefits have become increasingly commonplace, with a growing number of corporations including fertility coverage in employee health plans to attract and retain talent.

FERTILITY SERVICES MARKET TRENDS:

Rising Prevalence of Infertility Worldwide

The rising prevalence of infertility is a critical driver shaping the fertility services market. Postponement of childbearing, sedentary lifestyles, environmental pollutant exposure, and growing incidences of reproductive health disorders are collectively expanding the infertility burden across global populations. According to the World Health Organization's first global guideline on infertility released in November 2025, infertility affects about one in six people of reproductive age, highlighting its scale as a major public health issue and need for wider access to prevention, diagnosis, and treatment. Both male and female infertility rates have trended upward in numerous countries, sustaining consistent demand for medically assisted reproduction. In response to the issue, governments and health organizations have expanded awareness campaigns and subsidized treatments. The increasing acceptance of infertility as a legitimate medical condition has normalized seeking treatment, which has expanded the pool of patients and ensured long-term market demand.

Technological Advancements in Reproductive Medicine

Rapid technological innovation is transforming reproductive medicine, making assisted reproduction more effective and personalized. Advancements in preimplantation genetic testing, embryo selection algorithms, time-lapse imaging, and cryopreservation methods have significantly improved procedural success rates. Artificial intelligence applications in embryo evaluation enable more data-driven clinical decisions, enhancing patient outcomes. In September 2025, Fairtility received FDA clearance for its CHLOE AI-powered embryo assessment platform, the first such device approved in the United States, enabling more objective, data-driven embryo evaluation in clinical IVF practice. Miniaturized laboratory systems and automation tools are improving procedural precision while reducing operational costs. Novel ovarian stimulation protocols and improved culture media are further contributing to higher live birth rates. These developments are attracting growing healthcare and biotechnology investments, positively influencing the fertility services market outlook as patients increasingly prefer evidence-based, technologically advanced reproductive care solutions.

Growing Social Acceptance and Awareness

Shifting cultural attitudes are playing a transformative role in expanding the utilization of fertility services globally. Historically stigmatized, fertility treatments are now widely regarded as legitimate and medically necessary interventions. Media representation and open public discourse have normalized reproductive health challenges, encouraging individuals and couples to proactively seek assistance. In March 2025, the UK's Human Fertilisation and Embryology Authority (HFEA) reported that nearly 72% of fertility patients were satisfied with their most recent treatment, reflecting growing comfort with fertility care and openness about outcomes. The rise of single parenthood by choice and LGBTQ+ family formation has broadened the demographic of fertility services users, diversifying demand patterns. Healthcare providers and advocacy organizations continue launching targeted awareness initiatives around reproductive health and fertility preservation options. These evolving fertility services market trends reflect a fundamental societal shift, sustaining growing demand for comprehensive fertility interventions worldwide.

FERTILITY SERVICES INDUSTRY SEGMENTATION:

Analysis by Cause of Infertility:

• Male Infertility
• Female Infertility

Female infertility contributes 62% to the market share. Female infertility can be described as a broad spectrum of reproductive disorders that impact a woman's ability to reproduce or maintain a pregnancy to term. The leading causes of female infertility include ovulatory dysfunction, tubal factor, uterine abnormalities, and conditions such as polycystic ovary syndrome, endometriosis, and premature ovarian failure. Compared to male infertility, the diagnostic and therapeutic strategies for female infertility are more complex and subtle, requiring a variety of therapies from hormonal to surgical and reproductive assistive therapies. The clinical complexity and associated burden of female reproductive disorders contribute significantly to the total demand for fertility care, from ovulation induction to in vitro fertilization and egg donation. Moreover, egg freezing for fertility preservation has emerged as a new market that has been expanding rapidly over the last few years, as women are now empowered to control their reproductive life plan in the context of delayed reproduction.

Analysis by Procedure:

• In Vitro Fertilization with Intracytoplasmic Sperm Injection (IVF with ICSI)
• Surrogacy
• In Vitro Fertilization Without Intracytoplasmic Sperm Injection (IVF without ICSI)
• Intrauterine Insemination (IUI)
• Others

In Vitro Fertilization with Intracytoplasmic Sperm Injection (IVF with ICSI) currently dominates the market with a share of 35%. This technique involves the injection of a single sperm directly into a mature egg, providing a highly targeted and effective approach for couples struggling with severe male factor infertility or unexplained infertility after failed conventional IVF cycles. Due to its proven efficacy and high fertilization success rates, combined with its compatibility with preimplantation genetic testing, IVF with ICSI has become the method of choice in the most advanced clinics worldwide for the selection of chromosomally normal embryos prior to uterine transfer. Sperm selection by MAC (magnetic-activated cell sorting) technique is used in men who have poor sperm morphology and/or low sperm counts. It is also useful in cases when fertilization fails in dietary procedures. Constant enhancement of laboratory techniques, improvements in ovarian stimulation regimens and the increased expertise of reproductive practitioners together are responsible for the success of ICSI, thereby making it the leader in the fertility techniques market.

Analysis by Service:

• Fresh Non-Donor
• Frozen Non-Donor
• Egg and Embryo Banking
• Fresh Donor
• Frozen Donor

Fresh non-donor dominates the market, with a share of 30%. Fresh non-donor services involve the use of a patient's own freshly retrieved eggs and partner-provided sperm to create embryos for immediate transfer, making it the most widely utilized fertility service pathway. This approach is preferred by couples seeking a biologically connected parenthood option without reliance on donor gametes, and it remains the first-line treatment option in most fertility clinics globally. The fresh non-donor cycle is favored for its natural approach, immediate embryo transfer capability, and the avoidance of complexities associated with cryopreservation protocols in uncomplicated cases. Its widespread adoption across both public and private fertility settings, combined with high patient familiarity and physician comfort with the procedure, sustains its leading market position. The growing volume of IVF and ICSI cycles being performed globally, along with favorable clinical guidelines recommending fresh transfers in appropriate candidates, reinforces the prominence of this segment within the broader fertility services market forecast.

Analysis by End-User:

• Fertility Clinics
• Hospitals
• Surgical Centres
• Clinical Research Institutes
• Cryobanks

Fertility clinics represent the leading segment, with a market share of 41%. These are specially designed facilities that are equipped with the latest reproductive laboratories, diagnostic facilities, and staff specifically trained to deal with infertility evaluation and management. Fertility clinics provide an integrated service delivery that encompasses consultation, hormonal analysis, ultrasound follow-up, egg retrieval procedures, embryology laboratory facilities, embryo transfer, and follow-up care in a single setting. The concentration of expertise, infrastructure, and patient focus makes fertility clinics the point of choice for patients seeking assisted reproductive technology services. In November 2025, INVO Fertility, Inc. announced plans to acquire Indiana-based Family Beginnings, expanding its national clinic network to meet rising patient demand and reflecting ongoing consolidation in the fertility sector. Many leading clinics have also established partnerships with genetic testing laboratories and cryobanks, enabling seamless integration of preimplantation genetic testing and fertility preservation into their service offerings.

Regional Analysis:

• Europe
• North America
• Asia Pacific
• Middle East and Africa
• Latin America

Asia Pacific, accounting for 30% of the share, enjoys the leading position in the market. The region's dominance is underpinned by several interconnected factors that collectively drive robust demand for fertility services across its diverse economies. The region includes some of the most populated countries in the world, such as China, India, Japan, South Korea, and Australia, each with unique fertility service demand patterns influenced by demographic factors, healthcare policies, and cultural perceptions of assisted reproduction. The rapidly aging population in the East Asian economies, combined with the high prevalence of infertility in South Asian markets, provides a wide patient base. Government-backed fertility assistance initiatives, such as IVF cycle subsidies in Japan, Australia, and South Korea, have greatly enhanced the accessibility and affordability of fertility services. At the same time, the growing number of technologically advanced fertility centers and the rising medical tourism presence in countries like India and Thailand continue to enhance the fertility services capacity in the Asia Pacific region, making it the largest regional contributor to the global market.

KEY REGIONAL TAKEAWAYS:

North America Fertility Services Market Analysis

North America represents one of the most advanced and well-established regional markets for fertility services, driven by a combination of demographic shifts, technological leadership, and favorable policy environments. The region benefits from a high concentration of accredited fertility centers, sophisticated reproductive laboratory infrastructure, and a robust network of highly trained reproductive specialists dedicated to delivering comprehensive assisted reproductive care. Rising infertility prevalence linked to delayed childbearing, lifestyle-related health conditions, and increasing family formation among diverse demographics, including same-sex couples and single individuals, continues to expand the patient base significantly. Employer-sponsored fertility benefits and state-level insurance mandates have substantially improved treatment affordability and accessibility across broader population segments. The strong culture of innovation in reproductive medicine, combined with growing patient awareness, increasing investment in fertility technologies, and expanding clinic networks, reinforces North America's prominent and sustained position within the global fertility services market.

United States Fertility Services Market Analysis

The United States is the most advanced and mature fertility services market in the world, with a high level of concentration of accredited fertility centers, a complex fertility services ecosystem, and a well-established regulatory framework led by professional associations such as the Society for Assisted Reproductive Technology. The demand for fertility services in the United States is fueled by a combination of demographic and social trends, including the pervasive trend of delayed childbearing, the high prevalence of infertility in the general population, and the growing trend of family formation among same-sex couples. The availability of fertility benefits through employers has increased substantially, with an increasing number of Fortune 500 companies offering comprehensive fertility benefits as part of their employees' health benefits, making fertility treatments that were hitherto cost-prohibitive more accessible to patients. State-based insurance mandates requiring coverage for fertility diagnostics and treatments have also widened the pool of eligible patients and made fertility treatments more accessible. The culture of innovation in the United States reproductive medicine industry, along with high patient engagement, makes the United States the largest and most vibrant national fertility services market in the world.

Europe Fertility Services Market Analysis

Europe represents the second largest regional market for fertility services, supported by well-funded public healthcare systems in many member states and a long-established tradition of reproductive medicine research and clinical excellence. Countries such as Spain, Denmark, the Czech Republic, and the United Kingdom have positioned themselves as leading destinations for fertility treatments, attracting significant volumes of patients from both within Europe and internationally through medical tourism. In February 2025, Poland reinstated public funding for in-vitro fertilization (IVF), leading to its first IVF-conceived babies under the scheme and making all EU member states provide some level of public fertility treatment funding. The European fertility services landscape is characterized by a combination of publicly funded fertility treatment cycles and a thriving private clinic sector, with the balance varying considerably across different national healthcare systems. Regulatory frameworks governing donor anonymity, surrogacy, and embryo storage policies differ significantly across European jurisdictions, influencing patient cross-border movements and clinic specialization strategies.

Asia Pacific Fertility Services Market Analysis

The Asia Pacific has turned out to be the most rapidly growing market for fertility care. The growing demand for fertility care in the Asia Pacific is fueled by a number of factors, including the demographic trend, advancements in the healthcare infrastructure, and the changing attitudes of society towards fertility care. The rising incidence of infertility, due to late marriage and childbearing, environmental conditions, and lifestyle-related health issues, is increasing the patient base in the East and South Asian markets. Government support in Japan and South Korea to provide subsidies for fertility care is actively working to overcome the cost constraints and fuel the demand. The rapid development of a network of fertility clinics and the rising trend of medical tourism in India and Thailand is further strengthening the competitiveness of the Asia Pacific market in the global arena.

Latin America Fertility Services Market Analysis

Latin America is a steadily expanding market for fertility care, fueled by the growing awareness of infertility, private investments in the healthcare sector, and favorable medical tourism trends. Brazil, Mexico, Colombia, and Argentina have become the hubs for fertility care in Latin America, providing affordable fertility treatments that lure local as well as foreign patients. The rising levels of urbanization, changing lifestyles, and postponement of parenthood are contributing to the rising incidence of infertility in Latin America, which in turn is fueling the demand for various fertility treatments. Although fertility care is not easily accessible in rural and lower socioeconomic settings due to cost considerations, the increasing development of private fertility centers in major cities is slowly bridging the gap in fertility treatment accessibility in Latin America.

Middle East and Africa Fertility Services Market Analysis

The Middle East and Africa represent an emerging market for fertility services, characterized by significant growth potential amid evolving healthcare infrastructure and increasing social awareness of reproductive health. The high rates of infertility in the region, coupled with the cultural and religious values of family expansion, create a latent demand for fertility services. Countries such as the United Arab Emirates, Saudi Arabia, South Africa, and Israel have developed the infrastructure for advanced fertility clinics to attract patients from the region. Despite regulatory and cultural constraints that limit certain procedures such as surrogacy and gamete donation in some jurisdictions, the market continues to expand steadily, driven by rising healthcare spending, improving medical capabilities, and a growing population of treatment-seeking individuals.

COMPETITIVE LANDSCAPE:

The global fertility services market is moderately fragmented in terms of competitive intensity, with a combination of large integrated healthcare conglomerates, specialized fertility chain clinics, and standalone fertility clinics operating in different geographies. Market players are increasingly resorting to consolidation strategies, with private equity-funded acquisitions and mergers fueling the creation of large fertility clinic chains operating across several countries. Market leaders are diversifying their service offerings by investing in advanced reproductive technologies, lab infrastructure, and specialization, while at the same time expanding geographically to capitalize on high-growth fertility markets. Partnerships with genetic testing firms, embryo cryopreservation experts, and digital health platforms are also aiding players in providing more holistic and tech-enabled fertility solutions. Pricing competition and visibility of patient outcomes are reshaping the competitive environment, with patients increasingly using success rate data and reviews to select their fertility service provider. The industry is also facing challenges such as differences in regulations in various markets, a shortage of skilled reproductive specialists, and limited reimbursement in most regions.

The report provides a comprehensive analysis of the competitive landscape in the fertility services market with detailed profiles of all major companies, including:

• Instituto Bernabeu Group
• INVO Bioscience, Inc.
• Monash IVF Group
• Apollo Hospitals Enterprise Ltd.
• CARE Fertility Group Ltd.
• Carolinas Fertility Institute
• Genea Limited
• The Cooper Companies, Inc.
• Virtus Health Group
• Vitrolife Sweden AB
• The Johns Hopkins Health System Corporation
• Medicover AB (publ)
• OvaScience, Inc.
• Progyny, Inc.
• Xytex Corporation

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the fertility services market?

2. What is the future outlook of the fertility services market?

3. What are the key factors driving the fertility services market?

4. Which region accounts for the largest fertility services market share?

5. Which are the leading companies in the global fertility services market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Fertility Services Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Breakup by Cause of Infertility
• 5.5 Market Breakup by Procedure
• 5.6 Market Breakup by Service
• 5.7 Market Breakup by End-User
• 5.8 Market Breakup by Region
• 5.9 Market Forecast

6 Market Breakup by Cause of Infertility

• 6.1 Male Infertility
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Female Infertility
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Procedure

• 7.1 In Vitro Fertilization with Intracytoplasmic Sperm Injection (IVF with ICSI)
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Surrogacy
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 In Vitro Fertilization Without Intracytoplasmic Sperm Injection (IVF without ICSI)
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Intrauterine Insemination (IUI)
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Service

• 8.1 Fresh Non-Donor
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Frozen Non-Donor
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Egg and Embryo Banking
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Fresh Donor
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Frozen Donor
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by End-User

• 9.1 Fertility Clinics
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Hospitals
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Surgical Centres
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Clinical Research Institutes
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast
• 9.5 Cryobanks
  • 9.5.1 Market Trends
  • 9.5.2 Market Forecast

10 Market Breakup by Region

• 10.1 Europe
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 North America
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Asia Pacific
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Middle East and Africa
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast
• 10.5 Latin America
  • 10.5.1 Market Trends
  • 10.5.2 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Instituto Bernabeu Group
  • 15.3.2 INVO Bioscience, Inc.
  • 15.3.3 Monash IVF Group
  • 15.3.4 Apollo Hospitals Enterprise Ltd.
  • 15.3.5 CARE Fertility Group Ltd.
  • 15.3.6 Carolinas Fertility Institute
  • 15.3.7 Genea Limited
  • 15.3.8 The Cooper Companies, Inc.
  • 15.3.9 Virtus Health Group
  • 15.3.10 Vitrolife Sweden AB
  • 15.3.11 The Johns Hopkins Health System Corporation
  • 15.3.12 Medicover AB (publ)
  • 15.3.13 OvaScience, Inc.
  • 15.3.14 Progyny, Inc.
  • 15.3.15 Xytex Corporation